Analyst
Chief of R&D Strategy
Equibles does not estimate personal net worth.
Allen Yang is recorded as Analyst at Chief of R&D Strategy. Xencor Inc reported in an 8-K filed July 3, 2023 that Allen Yang was terminated as executive officer, effective June 30, 2023. Xencor Inc reported in an 8-K filed April 26, 2023 that Allen Yang resigned as executive officer, effective May 1, 2023. Allen Yang has spoken on 4 earnings calls and 1 other investor event across 1 company, most recently for Summit Therapeutics Inc. on July 23, 2026. Summit Therapeutics Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Summit Therapeutics Inc. includes Glyn Edwards (CEO), Mahkam Zanganeh (CEO, COO and Board Member), Robert Duggan (CEO and Board Member) and 7 others.
“On June 30, 2023, Dr. Yang signed a separation agreement terminating his employment with the Company as of 5:00 p.m., Pacific time, on June 30, 2023.”
“Effective May 1, 2023, Dr. Allen Yang will step down from his role as an executive officer of the Company.”
“I just want to remind everyone that HARMI-III was our global study, so it was started globally at the same time. There are some differences. Certain regions open very quickly and enroll very quickly.”
“Yeah, so certainly we have, over the course of 2026, we have our final PFS readout for Harmony 3 Squamous. Shortly thereafter, in the first half, rather, of 2027, we have the non-squamous readout for PFS as well.”
“Remember, this study was designed way back in 23 right and since then we've had the Harmony 2 and the Harmony 6 readout our mission is always to been bring this very important medicine which we think is a game-changer to patients as soon as possible right and I think the Harmony 2 and now the Harmony 6 data gives us…”
“I don't have much to add except that, you know, the precedent in this space has not been, it's not been needed to hit OS to get an approval.”
“I think we would, of course, would want to hit OS and be statistically significant. However, if you look at the precedence of previous approvals in this space, they have not required OS for when PFS has been adequate.”
Chief of R&D Strategy
Analyst
Source not stated
Source not stated
Source not stated
Start not stated–2023-06-30
Biotechnology · Healthcare
